Solutions for CAF immunomodulation in TME

Relying on the technology platform of the tumor microenvironment center, Alfa Cytology provides global collaborators with solutions and related services to study the relationship between tumor immunity and cancer-associated fibroblasts (CAFs) in the tumor microenvironment (TME), helping them to rapidly achieve their research goals.

Introduction

Cancer -associated fibroblasts (CAFs) are important components of the tumor microenvironment and are the most numerous cell population mediating tumor immunosuppressive effects. In solid tumor tissues, CAFs are mostly located at the margins of tissues or infiltrated in tumor tissues, and have an important role in tumor immune regulation. It regulates the recruitment and function of intrinsic and adaptive immune cells in the tumor microenvironment by secreting a variety of growth factors, chemokines, and proteases. In addition, the extracellular matrix secreted by CAF plays an important role in shaping the immunosuppressive properties of the tumor microenvironment as well as the formation of a hypoxic environment. It is necessary to investigate the regulatory role of CAFs in the tumor microenvironment on the infiltration and function of intrinsic and adaptive immune cells, and the related mechanisms, in order to provide a scientific basis for further research on targeting CAFs for antitumor immunotherapy.

Solutions

Cancer-associated fibroblasts (CAFs), as important components of TME, can influence the tumor immune microenvironment through direct cell-cell interactions and secretion of cytokines, and play an important role in regulating tumor immunity. Currently, a number of drugs targeting CAFs have been developed for tumor immunotherapy, including peripatetic cellular immunotherapy targeting fibroblast activation protein o (FAPo) specific T cells, DNA vaccines targeting FAPo peptides, and whole tumor cell vaccines regulating FAPo expression. However, the role of CAF in different stages of cancer cell metastasis is not yet clear. More in-depth studies on the interactions between CAFs and immune cells and the mechanisms of CAF immunomodulatory effects on tumors are needed in the future to better understand the pathogenesis of tumors and provide new molecular targets for clinical treatment of tumors.

Alfa Cytology has established a tumor microenvironment technology platform and developed several emerging technologies through which it helps global collaborators to deeply explore the relationship between tumor immunity and CAFs in the tumor microenvironment (TME), hoping to find potential targets for tumor therapy in the process and provide new ideas for clinical anti-tumor treatment.

Key technologies

Microfluidic technology can achieve single-cell manipulation at the order of magnitude, and has become one of the most promising single-cell analysis techniques in recent years. The application of microfluidic technology in single-cell pairing, fusion, migration, and cell-to-cell immune response is discussed, and the application prospects of microfluidic microarrays are prospected with organ-on-a-chip as an example. Using this technology, it is possible to deeply study the relationship between tumor immunity and CAFs in the tumor microenvironment (TME), hoping to find potential targets for tumor therapy in the process and provide new ideas for clinical anti-tumor treatment.

Combined immunofluorescence assays, cellular immunohistochemistry assays and western blot can provide technical support to explore the immune regulation of cancer-associated fibroblasts (CAFs) and tumors in the tumor microenvironment (TME).

Alfa Cytology is committed to supporting scientists in making breakthrough scientific discoveries and developing new applications to accelerate new drug discovery and scientific diagnosis and treatment. Our high-performance scientific instruments and high-value solutions enable scientists to explore the mysteries of life at the tumor microenvironment level. Please tell us your project requirements, and we will provide you with a full service from solution to report. If you have any questions, please feel free to contact us.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.